HeraMED Limited Total Assets
HeraMED Limited total assets. Based on the latest financial reports, HeraMED Limited (1I4) holds total assets worth €1.49 Million EUR (≈ $1.74 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see HeraMED Limited (1I4) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of HeraMED Limited (2018–2025)
Total assets of HeraMED Limited from 2018 to 2025. This chart illustrates how HeraMED Limited's total assets have evolved over time, based on quarterly financial data. See today's stock price for HeraMED Limited for real-time trading data and today's change.
HeraMED Limited - Asset Composition Analysis
HeraMED Limited Total Assets Breakdown (December 2025)
HeraMED Limited total assets breakdown as of December 2025. HeraMED Limited's total assets of €1.49 Million consist of 97.2% current assets and 2.8% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 91.9% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how HeraMED Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is HeraMED Limited's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: HeraMED Limited's current assets represent 97.2% of total assets in 2025, an increase from 55.1% in 2018.
- Cash Position: Cash and equivalents constituted 91.9% of total assets in 2025, up from 73.0% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 21.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
HeraMED Limited Competitors by Total Assets
Key competitors of HeraMED Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥5.03 Billion |
|
Xiangyu Medical Co. Ltd. A
SHG:688626
|
China | CN¥3.27 Billion |
|
HOB Biotech Group Corp Ltd
SHG:688656
|
China | CN¥916.43 Million |
|
Tellgen Corp
SHE:300642
|
China | CN¥2.01 Billion |
|
Dirui Industrial Co Ltd
SHE:300396
|
China | CN¥2.57 Billion |
|
EBR Systems Inc
AU:EBR
|
Australia | AU$97.29 Million |
|
Pulsenmore Ltd
TA:PULS
|
Israel | ILA120.34 Million |
|
Adherium Ltd
AU:ADR
|
Australia | AU$4.16 Million |
HeraMED Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.49 | 3.52 | 4.28 |
| Quick Ratio | 4.49 | 3.17 | 4.14 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €1.13 Million | €2.66 Million | €1.69 Million |
HeraMED Limited - Advanced Valuation Insights
This section examines the relationship between HeraMED Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 49.46 |
| Latest Market Cap to Assets Ratio | 18.57 |
| Asset Growth Rate (YoY) | -66.8% |
| Total Assets | €1.49 Million |
| Market Capitalization | $27.68 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values HeraMED Limited's assets at a significant premium (18.57x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: HeraMED Limited's assets decreased by 66.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for HeraMED Limited (2018–2025)
The table below shows the annual total assets of HeraMED Limited from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €1.49 Million ≈ $1.74 Million |
-66.75% |
| 2024-12-31 | €4.48 Million ≈ $5.24 Million |
+60.62% |
| 2023-12-31 | €2.79 Million ≈ $3.26 Million |
-54.31% |
| 2022-12-31 | €6.11 Million ≈ $7.14 Million |
+33.14% |
| 2021-12-31 | €4.59 Million ≈ $5.37 Million |
+10.65% |
| 2020-12-31 | €4.15 Million ≈ $4.85 Million |
-19.38% |
| 2019-12-31 | €5.14 Million ≈ $6.01 Million |
-34.29% |
| 2018-12-31 | €7.83 Million ≈ $9.15 Million |
-- |
About HeraMED Limited
HeraMED Limited, a medical data and technology company, develops, manufactures, and sells home-based maternity monitoring technology in Australia and the United States. It provides HeraBEAT, a medical device for fetal and maternal heart rate used by pregnant women; and HeraCARE, a digital maternity and women's health platform that focuses on improving clinical outcomes while supporting more effic… Read more